Solventum (NYSE:SOLV) Stock Rating Upgraded by Wells Fargo & Company

Solventum (NYSE:SOLV) was upgraded by stock analysts at Wells Fargo & Company to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other brokerages also recently issued reports on SOLV. BTIG Research reiterated a “buy” rating and issued a $100.00 price target on shares of Solventum in a research note on Friday, February 27th. KeyCorp increased their price objective on shares of Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Mizuho set a $100.00 price objective on shares of Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $93.70.

Solventum Price Performance

Shares of NYSE SOLV opened at $67.26 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The company has a market cap of $11.67 billion, a price-to-earnings ratio of 7.58, a price-to-earnings-growth ratio of 1.10 and a beta of 0.40. The stock’s 50-day moving average is $75.13 and its two-hundred day moving average is $75.82. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter last year, the business posted $1.41 EPS. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Analysts forecast that Solventum will post 6.58 EPS for the current fiscal year.

Solventum announced that its board has approved a stock repurchase plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to reacquire up to 7.5% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the stock in a transaction on Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Solventum

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Clifford Capital Partners LLC boosted its holdings in Solventum by 3.1% during the second quarter. Clifford Capital Partners LLC now owns 269,790 shares of the company’s stock worth $20,461,000 after buying an additional 8,085 shares in the last quarter. Nordea Investment Management AB increased its holdings in Solventum by 3.5% in the third quarter. Nordea Investment Management AB now owns 758,847 shares of the company’s stock valued at $54,880,000 after buying an additional 25,987 shares in the last quarter. LSV Asset Management lifted its position in shares of Solventum by 364.5% during the 3rd quarter. LSV Asset Management now owns 35,122 shares of the company’s stock valued at $2,564,000 after acquiring an additional 27,561 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Solventum by 15.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock valued at $22,469,000 after acquiring an additional 40,812 shares during the period. Finally, Candriam S.C.A. boosted its stake in shares of Solventum by 48.6% during the 3rd quarter. Candriam S.C.A. now owns 80,975 shares of the company’s stock worth $5,911,000 after acquiring an additional 26,481 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.